TransMedics Group (NASDAQ:TMDX) Lowered to Strong Sell Rating by Zacks Research

by · The Cerbat Gem

TransMedics Group (NASDAQ:TMDX – Get Free Report) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Monday,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research report on Tuesday, June 9th. Piper Sandler dropped their price target on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. TD Cowen reiterated a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a report on Wednesday, July 1st. UBS Group restated a “hold” rating on shares of TransMedics Group in a report on Tuesday, May 26th. Finally, Needham & Company LLC lowered their target price on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, TransMedics Group has a consensus rating of “Hold” and an average price target of $134.50.

Check Out Our Latest Stock Report on TransMedics Group

TransMedics Group Stock Performance

NASDAQ TMDX opened at $71.11 on Monday. The firm’s fifty day moving average price is $73.40 and its two-hundred day moving average price is $107.39. The stock has a market cap of $2.46 billion, a PE ratio of 16.16 and a beta of 1.89. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. TransMedics Group has a fifty-two week low of $60.10 and a fifty-two week high of $156.00.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The firm had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. During the same quarter in the previous year, the company posted $0.70 earnings per share. The firm’s revenue was up 21.2% on a year-over-year basis. On average, equities analysts expect that TransMedics Group will post 1.92 EPS for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TMDX. 180 Wealth Advisors LLC acquired a new stake in shares of TransMedics Group in the 2nd quarter worth about $276,000. Pacer Advisors Inc. increased its holdings in TransMedics Group by 79.8% during the 1st quarter. Pacer Advisors Inc. now owns 2,391 shares of the company’s stock worth $238,000 after purchasing an additional 1,061 shares in the last quarter. Militia Capital Management LLC purchased a new stake in shares of TransMedics Group in the first quarter worth approximately $2,088,000. Janus Henderson Group PLC lifted its holdings in shares of TransMedics Group by 2.1% in the first quarter. Janus Henderson Group PLC now owns 73,488 shares of the company’s stock valued at $7,306,000 after purchasing an additional 1,537 shares in the last quarter. Finally, Amundi lifted its holdings in shares of TransMedics Group by 31.2% in the first quarter. Amundi now owns 6,897 shares of the company’s stock valued at $686,000 after purchasing an additional 1,640 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

(Get Free Report)

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Featured Stories